oncgnostics develops highly reliable molecular biological tests for early detection, therapy decisions and follow-up care in cancer diagnostics. We have a strong one in the Jena University Hospital, from which we spun off almost eight years ago Cooperation partners at hand. With GynTect, a clarification test in cervical cancer screening, we approved our first diagnostic test with CE-IVD marking for the European market in 2015. It is very reliable in the detection of cancer and shows at an early stage whether there is any danger for the woman at all. This can prevent over-therapy. In addition, we conduct research in the areas of head and neck tumors and ovarian cancer.